04 Nov 2019
04 Nov 2019
|Date:||04 Nov 2019|
|Location:||Multiple Locations (ESR5, Lisbon, Champalimaud Foundation)|
|Employer:||Multiple Employers (ESR5, Lisbon, Champalimaud Foundation)|
|Job Type:||Full Time|
|Application starts:||04 Nov 2019|
|Application ends:||15 Dec 2019|
15 PhD Positions are available within the Marie Sklodowska Curie Innovative Training Network on:
Active monitoring of Cancer AS An AlternaTive To Surgery – CAST
CAST (www.cast-cancer.eu) is a Marie Sklodowska Curie Innovative Training Network funded by the European Commission.
When a patient is discovered to have cancer, one of the primary goals is to have the tumour removed by surgery. Although this provides excellent oncological control, it is associated with morbidity and functional problems in cancer survivors.
Recent studies have shown that the immediacy to perform a resection does not always lead to improved clinical outcome. Furthermore, cancer surgery can often lead to complications where the quality of life for the patient is compromised by toxic side effects and /or damage to waiting, active monitoring or surveillance, which are terms used to describe a monitoring strategy for cancer.
The concept may be antithetical but the functional advantage of these alternatives is clear even though there is some concern about the risk. Though the evidence is still weak, current studies suggest that with adequate selection and follow-up, this oncological risk is small. A major consideration for clinicians is now to maintain quality of life for all patients.
Our objective in this proposal is to implement novel approaches so that cancer surgery can be avoided, where we aim to:
(a) develop new monitoring technologies from industry so that the surveillance window can be increased to allow for better treatment options over time and to avoid surgery;
(b) develop new ‘watch and wait’ strategies in order to study the behaviour of the cancer so that any risks to the patient can be minimised leading to a better clinical outcome and;
© train a new generation of preclinical and clinical scientists to be able to implement this new concept as standard of care and to maximise the benefits of an active monitoring policy.
We will provide a structured 3-year cutting-edge PhD training programme in and beyond the fields of cancer and its biological basis, surgery, diagnostic tools (e.g. genetic, molecular diagnostic), medical physics and optical physics.
The earliest starting date will be November 1st, 2019. The latest will be October 31st September 2020.
We are looking for highly motivated and talented PhD students holding a Master’s degree or Bachelor’s degree (UK) in scientific fields like biology or chemistry. Excellent command of spoken and written English, communication skills as well as team spirit are essential. We are offering a competitive, interdisciplinary environment with a track record of intense mutual collaboration. In addition to the individual training-through-research our programme includes further elements such as workshops, summer schools, internships and secondments to the partners’ laboratories.
The following eligibility rules apply for participation in a Marie Sklodowska Curie Innovative Training Network:
Applicants must be in the first 4 years after obtaining their Master´s degree and/or Bachelor’s degree and must not have resided or carried out their main activity (work, studies, etc.) in the host country for more than 12 months in the 3 years immediately before the recruitment date.
In addition, local regulations of the host countries may apply. The salary is based on standard living, mobility and family allowances which are adapted to the respective country of recruitment.
To apply for the position at the Champalimaud Foundation, please send the following information to firstname.lastname@example.org and email@example.com , until December 15th 2019:
_ your complete CV
_ motivation letter
_ copies of University Master certificates or equivalents
_ contact details of two referees who can provide a letter of recommendation.
Please state the vacancy reference ( “CAST ESR5 ”) in the subject line.